Evidence map›Paper›PMID 35062359›Full record

Observational studyViruses2022

Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico.

Kame A Galán-Huerta, Samantha Flores-Treviño, Daniel Salas-Treviño, Paola Bocanegra-Ibarias, Ana M Rivas-Estilla, Eduardo Pérez-Alba, Sonia A Lozano-Sepúlveda, Daniel Arellanos-Soto, Adrián Camacho-Ortiz

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kame A Galán-HuertaCenter for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.ORCID 0000-0002-3495-0528
Samantha Flores-TreviñoDepartment of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.ORCID 0000-0003-1259-7425
Daniel Salas-TreviñoDepartment of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.ORCID 0000-0002-6755-0854
Paola Bocanegra-IbariasDepartment of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.ORCID 0000-0003-4602-3817
Ana M Rivas-EstillaCenter for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.ORCID 0000-0003-2311-2534
Eduardo Pérez-AlbaDepartment of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.ORCID 0000-0002-6642-2770
Sonia A Lozano-SepúlvedaCenter for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.
Daniel Arellanos-SotoCenter for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.
Adrián Camacho-OrtizDepartment of Infectious Diseases, School of Medicine, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.
Universidad Autónoma de Nuevo León · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 variants of concern (VOCs) or of interest (VOIs) causing vaccine breakthrough infections pose an increased risk to worldwide public health. An observational case-control study was performed of SARS-CoV-2 vaccine breakthrough infections in hospitalized or ambulatory patients in Monterrey, Mexico, from April through August 2021. Vaccination breakthrough was defined as a SARS-CoV-2 infection that occurred any time after 7 days of inoculation with partial (e.g., first dose of two-dose vaccines) or complete immunization (e.g., second dose of two-dose vaccines or single-dose vaccine, accordingly). Case group patients (

Indexed as

AdultAgedBreakthrough InfectionsCase-Control StudiesCOVID-19COVID-19 VaccinesFemaleHospitalizationHospitals, UniversityHumansMaleMexicoMiddle AgedPhylogenyPrevalenceSARS-CoV-2COVID-19 VaccinesCanSinoCOVID-19COVID-19 vaccinesDeltaLatin AmericaMexicoMuSARS-CoV-2surveillancevariant of concern

Identifiers

PMID35062359
PMCPMC8781434
OpenAlexW4205534792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.